Similar articles for PMID: 9845086

Year	Number of Results
1991	2
1992	1
1993	5
1994	5
1995	11
1996	3
1997	5
1998	13
1999	12
2000	8
2001	6
2002	4
2003	4
2004	7
2005	3
2006	4
2007	1
2008	2
2009	4
2010	2
2011	3
2012	5
2013	1
2014	1
2015	1
2016	1
2024	0

1

Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo.

Honess DJ, Hill SA, Collingridge DR, Edwards B, Brauers G, Powell NA, Chaplin DJ. Honess DJ, et al. Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):731-5. doi: 10.1016/s0360-3016(98)00300-9. Int J Radiat Oncol Biol Phys. 1998. PMID: 9845086

2

Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with (99m)Tc-sestamibi, (201)Tl chloride and (99m)Tc-HL91.

Kinuya S, Yokoyama K, Li XF, Bai J, Watanabe N, Shuke N, Takayama T, Bunko H, Michigishi T, Tonami N. Kinuya S, et al. Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1006-11. doi: 10.1007/s00259-002-0846-x. Epub 2002 May 17. Eur J Nucl Med Mol Imaging. 2002. PMID: 12173013

3

Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime).

Suzuki T, Nakamura K, Kawase T, Kubo A. Suzuki T, et al. Ann Nucl Med. 2003 Apr;17(2):131-8. doi: 10.1007/BF02988451. Ann Nucl Med. 2003. PMID: 12790362

4

[Biodistribution of hypoxic marker, 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime)].

Suzuki T, Nakamura K, Kawase T, Kubo A. Suzuki T, et al. Kaku Igaku. 2001 Jul;38(4):333-41. Kaku Igaku. 2001. PMID: 11530380 Japanese.

5

Anti-angiogenic therapy and chemotherapy affect 99mTc sestamibi and 99mTc-HL91 accumulation differently in tumour xenografts.

Kinuya S, Yokoyama K, Fukuoka M, Mori H, Shiba K, Watanabe N, Shuke N, Michigishi T, Tonami N. Kinuya S, et al. Nucl Med Commun. 2005 Dec;26(12):1067-73. doi: 10.1097/00006231-200512000-00004. Nucl Med Commun. 2005. PMID: 16264352

6

99mTc-HL91. Effects of low flow and hypoxia on a new ischemia-avid myocardial imaging agent.

Okada RD, Johnson G 3rd, Nguyen KN, Edwards B, Archer CM, Kelly JD. Okada RD, et al. Circulation. 1997 Apr 1;95(7):1892-9. doi: 10.1161/01.cir.95.7.1892. Circulation. 1997. PMID: 9107178

7

Accumulation of Tc-99m HL91 in tumor hypoxia: in vitro cell culture and in vivo tumor model.

Lee BF, Chiu NT, Hsia CC, Shen LH. Lee BF, et al. Kaohsiung J Med Sci. 2008 Sep;24(9):461-72. doi: 10.1016/S1607-551X(09)70003-8. Kaohsiung J Med Sci. 2008. PMID: 19073378 Free article.

8

Tumour hypoxia and technetium tracers: in vivo studies.

Abrantes AM, Serra E, Goncalves C, Oliveiros B, Laranjo M, Sarmento-Ribeiro AB, Rocha-Gonsalves A, Botelho MF. Abrantes AM, et al. Curr Radiopharm. 2012 Apr;5(2):99-105. doi: 10.2174/1874471011205020099. Curr Radiopharm. 2012. PMID: 22280110

9

The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies.

Stüben G, Stuschke M, Knühmann K, Horsman MR, Sack H. Stüben G, et al. Radiother Oncol. 1998 Aug;48(2):143-8. doi: 10.1016/s0167-8140(98)00006-1. Radiother Oncol. 1998. PMID: 9783885

10

Technetium-99m HL91 uptake as a tumour hypoxia marker: relationship to tumour blood flow.

Tatsumi M, Yutani K, Kusuoka H, Nishimura T. Tatsumi M, et al. Eur J Nucl Med. 1999 Feb;26(2):91-4. doi: 10.1007/s002590050364. Eur J Nucl Med. 1999. PMID: 9933342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

112 results

Results by year